HOME >> BIOLOGY >> NEWS
New strategy for treating allergic disorders

Ghent − Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders. VIB researchers associated with Ghent University, in collaboration with the Academic Medical Center (AMC) in Amsterdam, have shown that auto-antigens or allergens can be administered orally via the lactic acid bacterium. Based on this principle, which has been patented by VIB, ActoGeniX − a spin-off from VIB and Ghent University − is already developing a variety of biopharmaceutical medicines for a range of clinical indications.

The immune system

Every day our immune system combats harmful substances and micro-organisms that seek to penetrate our body. However, if our immune system is not working properly, we are subject to a variety of diseases. In the case of auto-immune diseases, the immune system no longer distinguishes between our bodys own substances and foreign substances and begins to attack our own tissues and organs. In other cases, the immune system responds mistakenly to harmless substances, such as the house dust mite, milk products, or pollen. This inappropriate immune system reaction to contact with such substances (allergens) is called an allergy. Today, 20% of the European population suffers from an allergy, which is twice as many sufferers compared to 15 years ago.

Lactococcus as supplier of remedies

In its natural form, the lactic acid bacterium (Lactococcus lactis) is a well-known food bacterium that has been used since time immemorial to convert milk into cheese and yoghurt. In the battle against chronic intestinal diseases, VIB researchers have been using L. lactis as a producer of a drug against gastroenteritis. The initial results of the clinical trials are promising.

Now, the bacterium is also being used to fight other disorders. There are a number of active substances for the treat
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
1-Aug-2007


Page: 1 2

Related biology news :

1. Does EPA have an adequate strategy to oversee nanotechnologies?
2. High blood pressure medication strategy proves effective in Hispanic women
3. Rutgers: GM/GMO/Biotech crop containment strategy
4. Scientists identify new strategy for preventing acute and chronic brain disease
5. International risk research strategy and funding needed for nanotech safety
6. Study shows metabolic strategy of stressed cell
7. Trojan horse strategy defeats drug-resistant bacteria
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Drug strategy makes cancer genes get lost in translation
10. Researchers develop new strategy for the treatment of CML
11. Nanotech safety needs specific government risk research strategy and funding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... , ... October 24, 2019 , ... World Cord Blood ... parents, doctors, nurses, and midwives to learn about the current and future uses of ... Cord blood is now being used to treat and cure over 80 different life-threatening ...
(Date:10/26/2019)... ... October 25, 2019 , ... The ... in La Plata, MD. Orofacial myofunctional disorders (OMDs) are abnormal movement patterns of ... speaks. This can include anything from difficulty swallowing and limited tongue movement to ...
(Date:10/22/2019)... ... October 22, 2019 , ... Greenberg Traurig, LLP’s global ... Deal Making in the Life Sciences Sector,” with German biotech strategy consulting firm, Catenion. ... at Greenberg Traurig’s Tokyo office . , Speakers from Greenberg Traurig and Catenion ...
Breaking Biology News(10 mins):
(Date:11/2/2019)... TORONTO (PRWEB) , ... October 31, 2019 , ... ... at Adaptive Biotechnologies in a live webinar on Friday, ... application in immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) ...
(Date:10/30/2019)... ... , ... While using cold plasma to kill cancer cells isn’t an entirely ... Mines & Technology are exploring new ways to regulate cold plasma technology to ... the technique would prove to be a drug-free, minimally invasive cancer treatment that would ...
(Date:10/29/2019)... ... ... CaroGen Corporation , a biotechnology company, today announced three distinguished additions ... Wands, MD, of Brown University , Dr. Steve Projan, PhD, FAAM, formerly ... of Wayne State University, formerly a professor at Yale University School of Medicine ...
(Date:10/29/2019)... Mass. (PRWEB) , ... October 29, 2019 , ... ... spectral signature of the skin*. Using Silios CMS-C multispectral imagers , researchers ... new approach can replace identification based on retinal imaging, face recognition, fingerprints and ...
Breaking Biology Technology:
Cached News: